Global Alternative Splicing Defects in Human Breast Cancer Cells

被引:6
|
作者
Oh, Jagyeong [1 ]
Pradella, Davide [2 ]
Kim, Yoonseong [1 ]
Shao, Changwei [3 ]
Li, Hairi [3 ]
Choi, Namjeong [1 ]
Ha, Jiyeon [1 ]
Di Matteo, Anna [2 ]
Fu, Xiang-Dong [3 ]
Zheng, Xuexiu [1 ]
Ghigna, Claudia [2 ]
Shen, Haihong [1 ]
机构
[1] Gwangju Inst Sci & Technol, Sch Life Sci, Gwangju 500712, South Korea
[2] CNR, Inst Mol Genet Luigi Luca Cavalli Sforza, Via Abbiategrasso 207, I-27100 Pavia, Italy
[3] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
新加坡国家研究基金会;
关键词
alternative splicing; breast cancer; exon skipping; intrinsically disordered regions; INTRINSICALLY DISORDERED REGIONS; MECHANISMS; MUTATIONS; LINE; CLASSIFICATION; ASSOCIATION; EXPRESSION; THERAPY; REVEALS;
D O I
10.3390/cancers13123071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Aberrant alternative splicing (AS) regulation plays a pivotal role in breast cancer development, progression, and resistance to therapeutical interventions. Indeed, cancer cells can adapt their own transcriptome by changing different AS programs, thus generating cancer-specific AS isoforms involved in every hallmark of cancer. Here, we investigated global AS errors occurring in human breast cancer cells by using RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation sequencing. Our results identified several dysregulated AS events potentially relevant for breast cancer-related biological processes and that provide a better comprehension of the molecular mechanisms that orchestrate the malignant transformation. Breast cancer is the most frequently occurred cancer type and the second cause of death in women worldwide. Alternative splicing (AS) is the process that generates more than one mRNA isoform from a single gene, and it plays a major role in expanding the human protein diversity. Aberrant AS contributes to breast cancer metastasis and resistance to chemotherapeutic interventions. Therefore, identifying cancer-specific isoforms is the prerequisite for therapeutic interventions intended to correct aberrantly expressed AS events. Here, we performed RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation sequencing (RASL-seq) in breast cancer cells, to identify global breast cancer-specific AS defects. By RT-PCR validation, we demonstrate the high accuracy of RASL-seq results. In addition, we analyzed identified AS events using the Cancer Genome Atlas (TCGA) database in a large number of non-pathological and breast tumor specimens and validated them in normal and breast cancer samples. Interestingly, aberrantly regulated AS cassette exons in cancer tissues do not encode for known functional domains but instead encode for amino acids constituting regions of intrinsically disordered protein portions characterized by high flexibility and prone to be subjected to post-translational modifications. Collectively, our results reveal novel AS errors occurring in human breast cancer, potentially affecting breast cancer-related biological processes.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells
    Ohe, Kenji
    Miyajima, Shinsuke
    Abe, Ichiro
    Tanaka, Tomoko
    Hamaguchi, Yuriko
    Harada, Yoshihiro
    Horita, Yuta
    Beppu, Yuki
    Ito, Fumiaki
    Yamasaki, Takafumi
    Terai, Hiroki
    Mori, Masayoshi
    Murata, Yusuke
    Tanabe, Makito
    Ashida, Kenji
    Kobayashi, Kunihisa
    Enjoji, Munechika
    Yanase, Toshihiko
    Harada, Nobuhiro
    Utsumi, Toshiaki
    Mayeda, Akila
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2018, 182 : 21 - 26
  • [22] Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing
    Shah, Kalpit
    Gagliano, Teresa
    Garland, Lisa
    O'Hanlon, Timothy
    Bortolotti, Daria
    Gentili, Valentina
    Rizzo, Roberta
    Giamas, Georgios
    Dean, Michael
    ONCOGENE, 2020, 39 (39) : 6172 - 6189
  • [23] Characterization of alternative splicing events and prognostic signatures in breast cancer
    Pihua Han
    Jingjun Zhu
    Guang Feng
    Zizhang Wang
    Yanni Ding
    BMC Cancer, 21
  • [24] Characterization of alternative splicing events and prognostic signatures in breast cancer
    Han, Pihua
    Zhu, Jingjun
    Feng, Guang
    Wang, Zizhang
    Ding, Yanni
    BMC CANCER, 2021, 21 (01)
  • [25] TMEM16A alternative splicing coordination in breast cancer
    Ifeoma Ubby
    Erica Bussani
    Antonio Colonna
    Giuseppe Stacul
    Martina Locatelli
    Paolo Scudieri
    Luis Galietta
    Franco Pagani
    Molecular Cancer, 12
  • [26] Targeting alternative splicing in cancer immunotherapy
    Han, Nan
    Liu, Zhaoqi
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [27] Alternative splicing of lncRNAs in human diseases
    Chen, Jiaxi
    Liu, Yawen
    Min, Jingyu
    Wang, Huizhi
    Li, Feifan
    Xu, Chunhui
    Gong, Aihua
    Xu, Min
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (03): : 624 - 639
  • [28] Correlations Between the Characteristics of Alternative Splicing Events, Prognosis, and the Immune Microenvironment in Breast Cancer
    Deng, Youyuan
    Zhao, Hongjun
    Ye, Lifen
    Hu, Zhiya
    Fang, Kun
    Wang, Jianguo
    FRONTIERS IN GENETICS, 2021, 12
  • [29] Alternative Splicing in Cancer and Immune Cells
    Bernard, Antoine
    Boidot, Romain
    Vegran, Frederique
    CANCERS, 2022, 14 (07)
  • [30] DSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3′-End Usage
    Elhasnaoui, Jamal
    Miano, Valentina
    Ferrero, Giulio
    Doria, Elena
    Leon, Antonette E.
    Fabricio, Aline S. C.
    Annaratone, Laura
    Castellano, Isabella
    Sapino, Anna
    De Bortoli, Michele
    CANCERS, 2020, 12 (06) : 1 - 23